Literature DB >> 201398

Serum and lipoprotein apolipoprotein B levels in normal subjects and patients with hyperlipoproteinaemia.

P N Durrington, C H Bolton, M Hartog.   

Abstract

Apolipoprotein B (apo B) levels were measured by radioimmunoassay in the serum and lipoproteins from normal subjects and patients with hyperlipoproteinaemia. The total serum apo B concentration in normal subjects was 0.91 +/- 0.16 g/l (mean +/- S.D.); in type IIa hyperlipoproteinaemia it was 2.24 +/- 0.61 g/l; in type IIb, 3.05 +/- 1.24 g/l; in type IV, 2.24 +/- 0.99 g/l; and in type V, 1.30 +/- 0.16 g/l. In normal subjects 5.6 +/- 2.1% (mean +/- S.D.) of total apo B was present in very low density lipoproteins (VLDL) and 93 +/- 9% in low density lipoproteins (LDL). Corresponding values for type IIa were 3.8 +/- 1.9% and 93 +/- 3%, for type IIb, 9.9 +/- 7.5% and 91 +/- 1%, for type IV, 16.9 +/- 9.5% and 81 +/- 9%, and for type V, 38.4 +/- 11.0% and 52 +/- 8%. The ratio of cholesterol to apo B in serum was decreased in types IIa, IIb and IV, and increased in type V whereas the ratio of triglyceride to apo B in serum was decreased in type IIa, normal in type IIb and increased in types IV and V. The ratio of cholesterol to apo B in VLDL was increased in types IIa, IIb and V, but normal in type IV, whereas in LDL, this ratio was normal in types IIa and V but reduced in types IIb and IV. The ratio of triglycerides to apo B in VLDL was normal in types IIa, IIb and IV but raised in type V. In LDL, this ratio was increased in types IIb and IV but normal in types IIa and V.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 201398     DOI: 10.1016/0009-8981(78)90038-4

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

1.  Serum apolipoproteins AI and B and lipoproteins in middle aged men with and without previous myocardial infarction.

Authors:  P N Durrington; L Hunt; M Ishola; J Kane; W P Stephens
Journal:  Br Heart J       Date:  1986-09

Review 2.  Diagnosis and treatment of apolipoprotein B dyslipoproteinemias.

Authors:  Allan Sniderman; Patrick Couture; Jacqueline de Graaf
Journal:  Nat Rev Endocrinol       Date:  2010-04-27       Impact factor: 43.330

3.  Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia, and familial hypercholesterolemia.

Authors:  B Teng; G R Thompson; A D Sniderman; T M Forte; R M Krauss; P O Kwiterovich
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

Review 4.  Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding.

Authors:  Allan D Sniderman; Patrick Couture; Seth S Martin; Jacqueline DeGraaf; Patrick R Lawler; William C Cromwell; John T Wilkins; George Thanassoulis
Journal:  J Lipid Res       Date:  2018-05-16       Impact factor: 5.922

5.  Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes.

Authors:  N Tolonen; C Forsblom; L Thorn; J Wadén; M Rosengård-Bärlund; M Saraheimo; M Feodoroff; V-P Mäkinen; D Gordin; M-R Taskinen; P-H Groop
Journal:  Diabetologia       Date:  2009-10-10       Impact factor: 10.122

6.  Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).

Authors:  V Charlton-Menys; D J Betteridge; H Colhoun; J Fuller; M France; G A Hitman; S J Livingstone; H A W Neil; C B Newman; M Szarek; D A DeMicco; P N Durrington
Journal:  Diabetologia       Date:  2008-10-30       Impact factor: 10.122

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.